Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
ClinicalTrials.gov · NCT05768945 · Registry updated: 2025-11-10
- Condition / research focus
- Diabetes
- Sponsor
- Brigham and Women's Hospital
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2022-11-30. Completion: 2023-12-31 (may be estimated). Results are posted in this registry.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Semaglutide (drug)
- DPP-4 inhibitor (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported